Therapy News and Research

RSS

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

GENFIT, today announces topline results of the phase 2 GOLDEN-505 trial in NASH. Due to the unexpected rate of resolution of NASH in patients randomized to placebo who had early NASH (NAS of 3, placebo response rate>57%), along with the high number of sites for a limited sample size, the study as initially designed did not enable the trial to meet directly the primary endpoint.

27 Mar 2015

Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

A Task Force convened by the American Thyroid Association released updated guidelines for the diagnosis and treatment of medullary thyroid carcinoma (MTC). The current document is the first revision of the original guidelines published in 2009.

26 Mar 2015

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk today announced the company will launch Novoeight (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A.

From Novo Nordisk 26 Mar 2015

Inergetics announces launch of branded CBD-based nutritional supplement

Inergetics,Inc., a world-class developer of NSF Certified nutritional and consumer health products, announced today the launch of Nulief, a branded nutritional supplement offering the holistic benefits associated with Cannabidiol (CBD).

26 Mar 2015

Rice University study reveals carbon nanotube fibers can provide two-way connection with neurons

Carbon nanotube fibers invented at Rice University may provide the best way to communicate directly with the brain.

26 Mar 2015

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer's disease. The article appears in the March 25 issue of the Journal of Neuroscience.

26 Mar 2015

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies’ portfolio.

26 Mar 2015

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation, a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.

26 Mar 2015

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.

26 Mar 2015

Limited anticancer role for preoperative statins in localised RCC setting

Statin use prior to undergoing nephrectomy is not associated with survival outcomes in patients with localised renal cell carcinoma, research suggests.

25 Mar 2015

IMDC prognostic model valid in second-line RCC therapy

The International Metastatic Renal Cell Carcinoma Database Consortium prognostic model can be applied to metastatic renal cell carcinoma patients receiving second-line targeted treatment, according to research published in The Lancet Oncology.

25 Mar 2015

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development.

25 Mar 2015

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate.

25 Mar 2015

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical, Inc., today announced promising results from a clinical study evaluating a novel hemodialysis access technique that has the potential to revolutionize vascular access for patients with chronic kidney disease without the use of traditional open surgery.

25 Mar 2015

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

Intravenous (IV) cosyntropin therapy was equivalent to epidural blood patch (EBP) in relieving pain from post-dural puncture headache (PDPH) with potential for fewer complications and lower costs, data from a randomized, controlled trial showed.

25 Mar 2015

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China.

25 Mar 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

Multimodality at the Center for Advanced Biomedical Imaging: an interview with Professor Mark Lythgoe, UCL

Imaging techniques used to live in medical physics departments, where physicists worked on them, but now we're seeing biologists, cell biologists and developmental biologists looking at cellular processes and it's those advances that are really enabling imaging to move forward in a way that it hasn't previously been able to...

From Bruker BioSpin Group 25 Mar 2015

Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

Early gains in pain relief, behavioral markers and function were not sustained in patients treated with platelet-rich plasma (PRP) injection for facet joint arthropathy, new research shows. Results were available at the 31st Annual Meeting of the American Academy of Pain Medicine.

25 Mar 2015

Therapy News and Research

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Inergetics announces launch of branded CBD-based nutritional supplement

Rice University study reveals carbon nanotube fibers can provide two-way connection with neurons

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Limited anticancer role for preoperative statins in localised RCC setting

IMDC prognostic model valid in second-line RCC therapy

Alternating sunitinib, everolimus not supported in advanced RCC

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

Personalized gene therapy to fight against cancer

Multimodality at the Center for Advanced Biomedical Imaging: an interview with Professor Mark Lythgoe, UCL

Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News